Skip to content
Parakho

Sai Life Sciences Ltd

NSE SAILIFEBSE 544306sailife.com

Q1 FY27, unaudited

Revenue
₹546.73 Cr
Profit after tax
₹71.34 Cr

As filed with the exchange, standalone basis.

Board meeting

Sai Life Sciences Ltd has given BSE notice of a board meeting on 05 Nov 2026 to consider Q2 FY27 results. Notice · Results calendar

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, standalone basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations546.73+13.19%2,153.23
Other income3.54−64.59%49.13
Total income550.27+11.61%2,202.36
Employee benefit expense161.68+13.39%617.73
Finance costs5.98−44.08%32.62
Depreciation & amortisation42.13+22.74%152.30
Total expenses454.94+9.61%1,738.18
Profit before tax95.33+22.25%456.17
Tax expense24.00+22.35%114.69
Profit after tax71.34+22.22%341.48
Total comprehensive income91.00+52.01%313.26
Earnings per share
Earnings per share, basic₹3.36₹16.27
Earnings per share, diluted₹3.33₹16.08

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

FY26 — unaudited, from the company’s filing with NSE. Source

Q1 FY27 results for every company Parakho holds

Earnings call

Q1 FY27

Sai Life Sciences reported Q1 FY27 revenue of INR553 crores, up about 12% year-over-year, with CRO revenue growing 26% and CDMO growing about 6%. Management said the quarter's performance was in line with expectations and reiterated confidence in a stronger second half driven by planned capacity expansion. The company discussed progress on peptides, XDC, formulation and AI initiatives, and reaffirmed its longer-term revenue growth and EBITDA margin guidance.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote.

Read the full summary

Filings

12 shown · 52 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Industry

Healthcare › Pharmaceuticals

Classification as published by BSE.

Companies also in Pharmaceuticals, in alphabetical order

All 196 companies in Pharmaceuticals

Page generated from filings held to 12 Oct 2026.